echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The world's most expensive drugs list

    The world's most expensive drugs list

    • Last Update: 2022-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The US GoodRx website announced the list of the top 10 most expensive drugs in the worl.


    The world's top 10 most expensive drugs list Novartis' SMA gene therapy Zolgensma $125 million orphan drugs

    10 Soliris® (eculizumab)

    Soliris® (eculizumab)

    Sulevar (eculizumab) is a monoclonal antibody that inhibits terminal complement (C5a and C5b) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome in adults and children syndrome (aHUS) and adult neuromyelitis optica spectrum disorder (NMOS.


    Suli Rui Adult and Pediatric Paroxysmal Nocturnal Hemoglobinuria Developed by Alexion Pharma, USA

    Packaging of Soliris and its availability

    09 Ravicti

    Ravicti

    Glyceryl phenylbutyrate is a small molecule of nitrogen binding agent developed by HorizonPharma for the long-term treatment of some patients with urea cycle disorder (UCD) aged 2 years or old.


    Glycerides phenylbutyrate HorizonPharma developed the drug for long-term treatment of patients with an annual per capita expenditure of $ 695,000

    Structure and listing of Ravicti

    08 Blincyto (blinatumomab)

    Blincyto (blinatumomab)

    Binatumomab is a bispecific antibody (CD3 and CD19) developed by Amgen for the treatment of Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (rrAL.


    blinatumomab is developed by Amgen for the treatment of Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia

    Mechanism of action and dosing cycle of Blincyto

    07 Brineura

    Brineura

    Brineura is an enzyme replacement therapy developed by BioMari.


    Brineura BioMarin develops first therapy for late-onset infantile neuronal ceroid lipofuscinosis with annual cost of up to $730,000

    Intracerebroventricular infusion system device diagram

    06 Folotyn (Pralatrexate)

    Folotyn (Pralatrexate)

    Pralatrexate is a small molecule inhibitor of folic acid metabolism developed by Allos Therapeutic.


    Pralatrexate Allos Therapeutics' first-in-class dihydrofolate reductase inhibitor for the treatment of relapsed or refractory peripheral T-cell lymphoma

    The structure and listing of Folotyn

    05 Luxturna

    Luxturna

    Luxturna is the first approved gene therapy injection developed by Spark Therapeutics for the treatment of Leber congenital amaurosis (LCA) caused by RPE65 gene mutation (the first approved in the United States at the end of 2017.


    Luxturna SparkTherapeutics Develops First Approved Gene Therapy Injection

    Schematic diagram of the mechanism of action of Luxturna

    04 Myalept

    Myalept

    Metriptine was developed by Amryt for the treatment of leptin deficiency complications in patients with congenital or acquired systemic lipodystrophy


    Metriptine was developed by Amryt for the treatment of leptin deficiency complications in patients with congenital or acquired systemic lipodystrop.


    Schematic diagram of the mechanism of action of Myalept

    03 Danyelza

    Danyelza

    Nocetuzumab is a monoclonal antibody targeting the ganglioside GD2 developed by Y-mAbs for the treatment of bone or bone marrow neuroblastoma


    A monoclonal antibody targeting the ganglioside GD2 for the treatment of neuroblastoma in the bone or bone marrow by Y-mAbs, the company 's annual treatment cost is about $970,000

    Danyelza Mechanism of Action and Treatment Cycle

    02 Zokinvy (Lonafarnib)

    Zokinvy (Lonafarnib)

    Lonafanib is a small molecule drug developed by EigerBioPharmaceuticals for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeria-like Laminopathy (PL) , which is an oral farnesyl transfer Enzyme inhibitor that reduces the accumulation of progerin in the nucleus by inhibiting the prenylation of progeri.


    Lonafanib EigerBioPharmaceuticals developed a small molecule drug for the treatment of Hutchinson-Gilford Progeria Syndrome and Progeria-like Laminopathy Approved by the.


    Zokinvy's structural formula

    01 Zolgensma

    Zolgensma

    OAV101 injection is an AAV gene drug developed by NovartisPharma AG for the treatment of Spinal Muscular Atrophy (SMA.


    OAV101 injection NovartisPharma AG developed an AAV gene drug for the treatment of spinal muscular atrophy and was first approved in the United States in 201 The annual treatment cost is about 12 million US dollars

    references:

    references:

    https:// https://https:// https://https://luxturnah.


    https://luxturnah.


    https://myale.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.